These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: In vivo antagonism of the behavioral responses to L-3-,4-dihydroxyphenylalanine by L-3-,4-dihydroxyphenylalanine cyclohexyl ester in conscious rats.
    Author: Matsushita N, Misu Y, Goshima Y.
    Journal: Eur J Pharmacol; 2009 Mar 01; 605(1-3):109-13. PubMed ID: 19168057.
    Abstract:
    To establish the neurotransmitter role(s) of L-3,4-dihydroxyphenylalanine (DOPA) in its own right, we attempted to clarify whether i.p. injection of a DOPA antagonist, DOPA cyclohexyl ester (CHE), would antagonize the behavioral responses of conscious rats to DOPA in the presence of 3-hydroxybenzylhydrazine (NSD-1015) (100 mg/kg i.p.), a central aromatic L-amino acid decarboxylase (AADC) inhibitor. DOPA-CHE (40, 60 and 100 mg/kg) elicited a dose-dependent partial antagonism against the increase in locomotor activity induced by DOPA (100 mg/kg i.p.). A low dose of DOPA-CHE (10 mg/kg) elicited full antagonism against the potentiating effect of a non-effective dose of DOPA (20 mg/kg) on the increase in locomotor activity induced by a dopamine D(2) agonist quinpirole (0.3 mg/kg s.c.). DOPA-CHE (100 mg/kg) elicited full antagonism against licking behavior induced by DOPA (100 mg/kg). We confirmed that DOPA (100 mg/kg) increased the striatal dopamine content but elicited no effect on locomotor activity in the presence of benserazide (50 mg/kg i.p.), a peripheral AADC inhibitor. DOPA also increased the dopamine content in the presence of NSD-1015 to a maximal degree similar to that in the presence of benserazide. Thus, we conclude that DOPA-CHE is a suitable DOPA antagonist that would be available under in vivo experimental conditions. DOPA plays a role in the neuromodulation of behavior.
    [Abstract] [Full Text] [Related] [New Search]